Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China

11/29/2021 | 10:00pm EST

BEIJING, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with AstraZeneca R&D China (“AstraZeneca – LSE/STO/Nasdaq: AZN”) for the joint development in China of next-generation sequencing (NGS)-based tumor-informed (personalized) minimal residual disease (MRD) tests for various solid tumor types. AstraZeneca plans to incorporate the co-developed tests for China-specific studies.

Under the agreement, the companies will jointly invest capital for this collaboration, and will work together to develop and validate the personalized, solid tumor MRD assays for cancer monitoring and recurrence in China. These assays will be developed based on the genetic analysis of the primary tumor from individual patients at the beginning of treatment. A joint committee will be established to oversee the product development.

For solid tumor clinical trials in China that incorporate the use of NGS-based personalized MRD tests, AstraZeneca plans to incorporate the aforementioned co-developed MRD test in China-specific studies, subject to fulfillment of individual study criteria. Upon both companies' further agreement, the scope of the agreement may also be expanded to include IVD registration and commercialization. This is an exclusive, multi-year collaboration agreement between both parties, with exclusivity contingent on certain requirements.

“We are happy to work with Genetron Health with the aim to collaboratively develop and potentially commercialize an NGS-based MRD assay to help in directing the right treatments to the right patients. We look forward to joining forces and leveraging both companies’ expertise, in the hope of bringing an innovative and effective diagnostic to benefit more cancer patients in China,” said Jing He, Senior Vice President, Head of R&D China, AstraZeneca.

“We are thrilled to partner with a leading oncology global company such as AstraZeneca, and we are proud that this partnership demonstrates the value of the initial solid tumor MRD data that we have generated so far from Genetron’s Mutation Capsule platform, the proprietary technology that we developed in-house,” said Sizhen Wang, co-founder and CEO of Genetron Health. “The agreement represents the first step of a long-term collaboration. Our goal is to develop a world-class MRD product, by combining AstraZeneca’s global leading position in oncology drug development and their invaluable insights, along with our diagnostic platform and lab expertise. We are very excited to continue working on developing more innovative diagnostic products and solutions for cancer patients.”

About Genetron’s MRD program in solid tumor and Mutation Capsule technology

Genetron’s MRD program in solid tumor is powered by its Mutation Capsule technology, which was developed in-house and has two distinctive features that are very beneficial in the development of liquid biopsy assays. This proprietary technology allows the detection of methylation alterations and mutations in one reaction, and thus it requires less blood while achieving high detection sensitivity. The second feature is the cell-free DNA (cfDNA) sample’s genetic and epigenetic information can be preserved and amplified in the Mutation Capsule library, and can be used for up to ten analyses without sacrificing sensitivity, enabling significant time and cost savings. In addition to the profiling of different panels of mutation and methylation markers, the library can also be used for low-depth whole genome sequencing to profile genome-wide parameters. It also has the function of de novo discovery of methylation sites that could have diagnostic value.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s plans, strategies and timelines to develop personalized MRD tests for solid tumors in China with AstraZeneca R&D China, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact
Hoki Luk
Email: hoki.luk@genetronhealth.com
Phone: +1 (408) 891-9255

Media Relations Contact
Yanrong Zhao
Genetron Health
Email: yanrong.zhao@genetronhealth.com


Primary Logo

Source: Genetron Holdings Limited

2021 GlobeNewswire, Inc., source Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.65% 8770 Delayed Quote.1.06%
GENETRON HOLDINGS LIMITED -2.90% 4.69 Delayed Quote.-23.11%
All news about ASTRAZENECA PLC
07:00aCORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with H..
BU
04:37aEnhertu granted Priority Review in the US for patients with HER2-positive metastatic br..
AQ
03:01aCline Scientific extends collaboration agreement with AstraZeneca
AQ
02:40aAstraZeneca's Enhertu Granted Priority Review by US Regulator
DJ
02:31aJens Lindberg takes office as CEO of Medivir on January 24
AQ
02:23aAstraZeneca-Daiichi Sankyo's Breast Cancer Drug Accepted For Priority Review in US
MT
02:06aProsecution Takes Over Case of 8 Medics Pinned for Misusing Covid-19 Vaccines
AQ
01:09aIsrael Reopens Borders To Entry By Foreign Nationals
AQ
01/14EMA lists rare spinal condition as side effect of AstraZeneca's COVID-19 shot
RE
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 079 M - -
Net income 2021 2 716 M - -
Net Debt 2021 24 814 M - -
P/E ratio 2021 54,7x
Yield 2021 2,35%
Capitalization 185 B 186 B -
EV / Sales 2021 5,83x
EV / Sales 2022 4,78x
Nbr of Employees 76 100
Free-Float -
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 119,68 $
Average target price 138,50 $
Spread / Average Target 15,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC1.06%181 019
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317